$CME

Hyperliquid policy group cites 2 flaws in CME lawsuit

The Hyperliquid Policy Center filed an amicus brief supporting the CFTC in its legal dispute with CME Group, arguing that CME lacks standing and its interests fall outside the Commodity Exchange Act's protections. CME sued over the CFTC's approval of Kalshi's perpetual futures contract, claiming it should be classified as a swap. The CFTC and HPC contend CME's arguments are flawed and that the exchange could list similar products if it chose to. The case could impact the U.S. perpetual futures m

Original reporting
Published Sep 9, 2026, 3:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 5:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Hyperliquid policy group cites 2 flaws in CME lawsuit — source image
Decision brief

The 30-second read

$CMENeutralMed
01

Why it matters

The brief adds a new legal dimension to CME's lawsuit, potentially influencing the court's decision and market perception of CME's regulatory risk.

02

Market read

The case could reshape the regulatory framework for perpetual futures, affecting CME and other U.S. exchanges.

03

What to watch

The CFTC's own motion to dismiss and the upcoming response deadline (Oct 2) could shift expectations before any court ruling.

Relevance 7/10Novelty 7/10Timing: current

Background

Hyperliquid Policy Center filed an amicus brief supporting the CFTC, arguing CME lacks standing and falls outside the Commodity Exchange Act's zone of interests.

Company-level read

Ticker impact

$CMENeutralMedium confidence
Context

CME Group is the defendant in a lawsuit against the CFTC, which faces a new amicus brief from Hyperliquid Policy Center seeking dismissal.

Expected impact

Short‑term volatility may rise; price could move modestly higher if dismissal is likely.

Evidence & confidence

The brief introduces fresh legal arguments but outcome remains uncertain; traders may watch CME's stock for reaction.

Market effects

The decision could influence the broader U.S. derivatives market and other exchanges offering perpetual contracts.

U.S. futures exchanges may see regulatory clarity, while offshore platforms remain unaffected.

Regulatory outcome may set precedent for how perpetual futures are classified worldwide.

Counterpoint

If the court dismisses the case, CME may lose leverage to challenge competitors, potentially hurting its market share.

Key entities

  • CME Group

    U.S. derivatives exchange suing the CFTC over perpetual futures classification.

  • Hyperliquid Policy Center

    Filed amicus brief supporting the CFTC against CME.

  • CFTC

    Defendant in CME's lawsuit; its policy on perpetual futures is under challenge.

Related articles

$CMELow

CME Group to Launch CME Securities Clearing on December 7 to Expand Clearing Capacity, Choice and Capital Efficiency in the U.S. Treasury Market

CME Group plans to launch CME Securities Clearing on December 7, 2026, pending regulatory approval. The new clearing house will offer capital-efficient clearing for U.S. Treasury cash and repo transactions, complying with SEC's central clearing mandate. It will support cross-margining, reducing margin requirements and improving liquidity. According to CME Group, this launch aims to provide market participants with more capacity and resilience amid U.S. debt reaching $40 trillion.

$CMELow

Hyperliquid Submits Amicus Brief Supporting Industry Innovation In U.S. Futures Trading

Hyperliquid and the Healthy Perps Coalition (HPC) filed an amicus brief supporting the CFTC's approval of perpetual futures contracts. The brief argues CME Group's lawsuit lacks standing and stifles innovation. HPC claims the CFTC's approval expanded the market, benefiting all exchanges. If CME succeeds, future innovations may face legal challenges, potentially slowing market development.

$CMEMed

CME to enter European dairy derivatives market

CME Group will enter the European dairy derivatives market, launching its own indices, futures, and options under an agreement with EEX. EEX plans to phase out its dairy business by the end of 2027. The transaction includes European butter and skimmed milk powder indices and is subject to closing conditions. CME cited the EU's significant role in global dairy production and exports, according to the USDA.

$CMEMedAI 8/10

This Stock Gets Paid When Markets Get Nervous

CME Group (CME) benefits from market uncertainty, as its futures and options exchanges see increased trading volume. Q2 2026 revenue was $1.7B, operating income $1.1B, and earnings $2.99 per share. August daily volume was up 6% YoY. CME pays a quarterly dividend of $1.30 and a variable dividend, totaling a 4.2% yield in 2025. The stock trades at ~24x earnings.